Lantern Pharma Inc. annual report, FY2023

Lantern Pharma Inc. — Fiscal 2023 Form 10-K Summary

Business context and reporting period

Lantern Pharma is a clinical-stage biotechnology company developing precision oncology therapies using its RADR^® artificial intelligence, machine-learning and biomarker platform. The filing covers the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter filing.

Lead clinical programs: LP-300 in Phase 2, LP-184 in Phase 1A, and LP-284 in Phase 1A.
LP-184’s central nervous system and brain-cancer development is being conducted through wholly owned Starlight Therapeutics under the name STAR-001.
The antibody-drug conjugate program remains in preclinical optimization, including a 2023 collaboration with Bielefeld University using cryptophycin payloads.
LP-100 is being repositioned for potential combination use with PARP inhibitors after the company closed its Danish Phase 2 trial in 2023.
RADR^® includes more than 60 billion oncology-related data points; management targets more than 100 billion by the end of 2024.

Financial performance and liquidity

Metric	2023	2022	Change
Revenue	$0	$0	No change
Research and development expense	$11.894 million	$8.603 million	Up 38%
General and administrative expense	$5.983 million	$5.830 million	Up 3%
Total operating expenses	$17.878 million	$14.433 million	Up 24%
Loss from operations	$(17.878) million	$(14.433) million	Loss increased
Interest income	$765,000	$204,000	Increased
Other income, net	$1.151 million	$(32,000)	Improved
Net loss	$(15.962) million	$(14.260) million	Loss increased 12%
Basic and diluted loss per share	$(1.47)	$(1.31)	Loss per share increased
Cash flow from operating activities	$(14.347) million	$(12.767) million	Use increased

Cash and cash equivalents were $21.938 million at December 31, 2023, compared with $37.202 million at December 31, 2022.
Marketable securities were $19.365 million, compared with $17.994 million in the prior year. Cash plus marketable securities totaled approximately $41.3 million.
Working capital was approximately $40.663 million.
Net cash used in investing activities was $930,000, principally reflecting net purchases of marketable securities.
Net cash used in financing activities was $500,000, primarily for repurchases of 145,348 shares.
The company had no long-term debt outstanding at year-end.
Management believes existing cash and cash equivalents will fund operating and capital requirements for at least 12 months from the filing date, but states that substantial additional funding will be required to complete planned clinical development.

Material changes versus the prior comparable period

R&D expense increased by $3.291 million, driven primarily by higher research studies, consulting and R&D payroll costs. LP-184, LP-300 and LP-284 were the largest program spending areas.
LP-184 entered Phase 1A during 2023, and LP-284 entered Phase 1A in the fourth quarter. The LP-300 HARMONIC trial remained in Phase 2.
Enrollment in the HARMONIC trial was challenging at U.S. sites, and the company planned to expand enrollment efforts in East Asian countries.
Starlight Therapeutics was formed in January 2023 to focus on LP-184’s CNS and brain-cancer indications.
The company engaged Fortrea as lead CRO for the LP-300 and LP-184 trials and for startup activities related to LP-284. It expects substantial payments over the following 18 to 24 months.
Interest income rose because of higher interest rates and investment activity. Other income improved because of unrealized investment gains and higher dividend income.
The remaining approximately $541,000 of Allarity escrow funds was returned to the company in August 2023; no Allarity expense was recorded in 2023.
Shares outstanding declined from 10.857 million at December 31, 2022 to 10.721 million at December 31, 2023, mainly because of share repurchases.

Guidance, outlook, commentary and unusual items

Management expects continuing and potentially increasing operating losses as clinical trials, manufacturing, intellectual-property activities and RADR^® development advance.
The company does not expect meaningful operating revenue unless it successfully completes development and obtains regulatory approval for one or more candidates. No candidate has received marketing approval.
Management expects additional financing may be required through equity, debt, grants, collaborations or licensing transactions. No external funding source is committed.
Future funding needs and timing depend on clinical-trial scope, enrollment, regulatory requirements, manufacturing costs, personnel growth, intellectual-property expenses and collaboration activity.
LP-300’s prior Phase 3 trials failed to meet overall prespecified endpoints; the current strategy relies on retrospective subgroup findings and biomarker-based patient selection. These historical findings may not predict future trial results.
LP-184 and LP-284 had not yet been administered to patients in the filing’s risk disclosures, creating uncertainty regarding clinical safety and tolerability.
The company relies substantially on CROs, academic institutions and contract manufacturers and has no internal manufacturing facilities or redundant supply arrangements.
As of the filing date, management reported no material cybersecurity incident and assessed disclosure controls and internal control over financial reporting as effective at the reasonable-assurance level. The external auditor was not required to provide an internal-control attestation because the company is an emerging growth company.
Key unusual or non-operating items included $765,000 of interest income, $1.151 million of other income, $1.068 million of stock-based compensation, and $500,000 of share repurchases.

Principal risks and contingencies

Limited operating history, no commercial product revenue and recurring losses may require substantial additional capital.
Clinical-trial enrollment, particularly for biomarker-defined populations, may be delayed or insufficient.
Regulatory approval is uncertain, and prior trial failures may make development and partnering more difficult.
Safety, efficacy and tolerability remain unresolved for all candidates; LP-300 historical adverse events included serious hypersensitivity and hemolysis reports.
Dependence on third-party CROs and manufacturers creates execution, quality, supply, scalability and regulatory risks.
Licensing agreements require development diligence, milestone payments and royalties; failure to satisfy obligations could jeopardize rights to key candidates.
Intellectual-property protection is uncertain. The RADR^® platform has no issued patents identified in the filing and relies substantially on trade secrets and pending applications.
Cash balances substantially exceed FDIC insurance limits, and marketable securities are exposed to interest-rate and market-value fluctuations.
Additional equity financing could dilute existing holders. Outstanding warrants and options represented 1.269 million potentially dilutive securities at year-end.
The common stock has historically been thinly traded and volatile.

Facts investors should verify

Actual cash runway, quarterly cash burn and the timing and terms of any future financing.
Enrollment progress, site expansion and interim or final data from the LP-300 HARMONIC trial.
Safety, pharmacokinetic and dose-escalation results from the LP-184 and LP-284 Phase 1A trials.
Whether RADR^®-identified biomarkers and patient-selection strategies demonstrate prospective clinical validation.
Outstanding milestone, royalty, licensing and CRO obligations, including payments that may resume under the AF Chemicals arrangements after January 15, 2025.
Manufacturing readiness, supply redundancy and cGMP compliance for LP-300, LP-184 and LP-284.
The status and enforceability of issued and pending patents, particularly for biomarker uses and the RADR^® platform.
The potential dilution from 1.091 million outstanding options and 177,998 outstanding warrants.